JINCHANG, China, Jan. 28, 2026 /PRNewswire/ — On January 25, State Grid Jinchang Power Supply Company adopted drone autonomous inspection technology to conduct special patrols on backbone power lines crossing railways, highways and key corridors. It built a digital inspection system with the “Intelligent Eagle Eye” system, solving power grid operation and maintenance challenges under extreme weather and complex terrain, and safeguarding power supply security.
Focused on technological empowerment, the patrol innovatively adopted a closed-loop model of “3D modeling prediction + intelligent precision inspection”. Based on the 3D point cloud model of lines to plan routes, drones equipped with infrared thermal imaging lenses and “Intelligent Eagle Eye” took off automatically, hovering to shoot key parts like towers and insulator strings, and uploading high-definition images in real time. They efficiently detected hidden hazards such as pin defects and micro-cracks, greatly improving inspection efficiency and defect recognition rate while reducing the risk of manual high-altitude operations.
So far, the company has completed refined drone patrols in 15 key cross-over sections, accurately identifying potential hazards. It will further deepen drone technology application, improve the “human-machine collaboration” model, strengthen power grid operation capabilities through technological innovation, and ensure stable winter power supply.

Đề xuất
Nebu Ease Portable Nebulizer Claims Evaluated: 2026 Consumer Research Report on Mesh Nebulizer Technology, Respiratory Comfort Features, and What Buyers Should Verify
ProstACT Global Phase 3 Study (Part 1) Achieves Primary Objectives
TrimRx Telehealth Weight Loss Platform Examined in 2026 Consumer Research Report on GLP-1 Medication Access, Pricing Transparency and Safety Considerations
Sherry Cummings, CEO of Gryphon Healthcare, Named One of the Top 50 Women to KNOW in Texas
Direct Meds GLP-1 Program Report 2026: Compounded Semaglutide and Tirzepatide Pricing, Telehealth Access, and Consumer Verification Factors
Keros Therapeutics Presents Additional Clinical Data from Its Rinvatercept Program at the 2026 MDA Clinical & Scientific Conference